Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biomarkers Distinguish Latent from Active TB

By LabMedica International staff writers
Posted on 02 Aug 2010
Multicytokine profiles of patients can determine if they have active or dormant tuberculosis (TB). More...


A pattern of two cytokines was reasonably good at differentiating between persons sick with TB and persons infected but not ill. In addition, a third cytokine looks promising in distinguishing between uninfected persons and infected individuals.

Cytokines are proteins that are secreted by cells and regulate the behavior of other cells by binding to receptors on their surfaces. This binding triggers a variety of responses, depending on the nature of the cytokine and the target cell.

In a study, carried out at Duke University Medical Center (Duke University; Durham, NC, USA), whole blood samples were collected from 71 people belonging to one of three groups: those with active TB, those with latent TB infection, and those who were not infected with Mycobacterium tuberculosis. The blood samples were exposed overnight with mitogen (positive control), saline (negative control), and a mixture of three tubercles bacillus antigens that stimulated an immune response. Scientists then measured the levels of 25 specific cytokines, to determine the presence of a pattern that could allow them to differentiate among the three groups.

Four cytokines had significantly greater response to stimulation in TB-infected persons (active or latent) than in uninfected persons: interferon gamma, IP-10, MCP-1, and IL-15. Of these, two cytokines had significantly greater responses to stimulation among persons with active TB than persons with latent TB: MCP-1 where the median response was 30,000 pg/mL in active TB and 11,100 pg/mL in latent TB. For IL-15 the median response in active TB was 152 pg/mL and 35 pg/mL in latent TB. A combination of MCP-1 and IL-15 at cutoffs of greater than 25,000 pg/mL and 80 pg/mL respectively, correctly categorized 10 of 12 active TB infections and 28 of 32 latent TB infections.

The resurgence of tuberculosis has resulted in the declaration of a global health emergency by the World Health Organization (WHO, Geneva, Switzerland, www.who.int). Every year, nearly half a million new cases of multidrug-resistant tuberculosis (MDR-TB) are estimated to occur worldwide. Jason Stout, M.D., M.H.S., assistant professor at Duke University, said, "Generally a culture is required to tell the difference between latent infection and active tuberculosis, but a culture usually requires weeks to deliver a result. A rapid test that could tell the difference between latent and active tuberculosis would be a major step forward.” The findings were reported at the American Thoracic Society International Conference held in New Orleans in May 2010.

Related Links:

Duke University Medical Center
WHO



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.